Related Experiment Video
Updated: May 19, 2026
Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Pneumococcal vaccines for children: a global public health priority
1Department of Paediatrics, Geneva University Hospitals and University of Geneva Medical School, Geneva, Switzerland.
Insights
Pneumococcal conjugate vaccines significantly reduce invasive pneumococcal diseases in children. These vaccines offer broad protection against bacterial infections like meningitis and pneumonia, improving public health.
Area of Science:
- Pediatrics
- Immunology
- Vaccinology
Background:
- Pneumococcal conjugated vaccines (PCVs) have been recommended for children globally for over ten years.
- Review focuses on the development and safety of currently available pediatric pneumococcal vaccines.
- Discussion includes the 13-valent pneumococcal conjugate vaccine (PCV13).
Observation:
- PCVs have demonstrated a significant decrease in invasive pneumococcal diseases (IPDs) in immunized regions.
- Impact observed not only in the primary target age group but also in unvaccinated younger and older populations.
- Effects on mucosal disease and nasopharyngeal carriage of Streptococcus pneumoniae were also examined.
Findings:
- Widespread immunization with PCVs led to a substantial reduction in IPDs, including bacteremia, pneumonia, and meningitis.
- The 13-valent pneumococcal conjugate vaccine (PCV13) has played a key role in disease reduction.
- Herd immunity effects were evident, protecting unvaccinated individuals across different age groups.
Implications:
- The success of current PCVs highlights their importance in pediatric public health.
- Future vaccine development aims for 'universal' vaccines to overcome serotype replacement issues.
- Continued research is needed to address challenges and enhance serotype-specific protection globally.
Abstract:
Pneumococcal conjugated vaccines have been recommended in children for over a decade in many countries worldwide. Here we review the development of pneumococcal vaccines with a focus on the two types currently available for children and their safety record. We discuss also the effect of vaccines, including the 13-valent pneumococcal conjugate vaccine, on invasive pneumococcal diseases in children, particularly bacteraemia, pneumonia and meningitis, as well as on mucosal disease and carriage. In regions where immunization was implemented in young children, the number of invasive pneumococcal diseases decreased significantly, not only in the target age group, but also in younger and much older subjects. Challenges and future perspectives regarding the development of new 'universal' vaccines, which could bypass the current problem of serotype-specific protection in a context of serotype replacement, are also discussed.
Related Concept Videos
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:30Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:29Pneumonia I: Introduction
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia III: Complications and Assessment
01:29Pneumonia II: Pathophysiology